期刊文献+

DNA修复基因XPA在非小细胞肺癌中的表达及其临床意义

THE EXPRESSION OF DNA REPAIR GENE XPA IN ADVANCED NON-SMALL CELL LUNG CANCER AND ITS CLINICAL SIGNIFICANCE
下载PDF
导出
摘要 目的:分析非小细胞肺癌(NSCLC)组织中DNA修复基因Xeroderma Pigmentosum Group A(XPA)的表达状况及其与临床病理特征的关系。方法:采用免疫组织化学方法(IHC)检测初治中晚期NSCLC患者癌组织中XPA的表达状况,采用χ2检验比较各亚组之间的XPA表达状况的差异。结果:109例NSCLC组织中XPA的阳性表达率为55.0%(60/109),其表达与性别、吸烟史有密切关系,在男性组中的阳性率(61.0%)显著高于女性组(37.0%)(P=0.030);吸烟组的XPA阳性率显著高于不吸烟组(分别为68.1%和45.2%,P=0.017);但在吸烟人群中,吸烟量不同的亚组间XPA的表达率未见明显差异。XPA阳性率在不同年龄、临床TNM分期、组织学类型或分化程度、淋巴结转移和远处转移亚组中的差异均无统计学意义(均P>0.05)。结论:XPA在NSCLC组织中的表达状况与性别、吸烟状况密切相关,并可能与NSCLC的发生有关。 Objective:To investigate the association between the expression of DNA repair gene XPA with the clinicopathology characteristics in patients with advanced non-small cell lung cancer (NSCLC) and its clinical significance. Methods: The expression, of XPA was examined with immunohistochemistry (IHC), the positive expression rate of XPA in different clinicopathology characteristic groups was analyzed. Re- sults: In 109 patients with NSCLC, the positive rate of XPA was 55.0% (60/109), and the expression rate in males was significantly higher than that in females (61.0% vs. 37.0%, P =0.030). The expression rate was also higher in smokers than in non-smokers (68.1% vs. 45.2%, P=0. 017). There were no sig- nificant differences in the expression of XPA among different ages, TNM stages, and pathological classifi- cation ( P 〉0.05 for all). Conclusion: In NSCLC cases, the expression status of XPA is markedly associ- ated with gender and smoking status. Thus, XPA may play a potential role in non-small cell lung cancer occur process.
出处 《广西医科大学学报》 CAS 2012年第3期364-367,共4页 Journal of Guangxi Medical University
基金 国家自然科学基金资助项目(No.30960436) 广西自然科学基金资助项目(No.桂科自0832234) 广西医疗卫生重点课题(No.重200967)
关键词 非小细胞肺癌 XPA 免疫组织化学 表达 non-smallpigmentosum group A pressloncell lung cancer xerodermaimmunohistochemistry ex
  • 相关文献

参考文献2

二级参考文献42

  • 1Wood RD. DNA repair in eukaryotes [J]. Annu Rev Biochem,1996,65:135-167.
  • 2Wood RD. Nucleotide excision repair in mammalian cells [J].J Boil Chem, 1997,272(38) :23465-23468.
  • 3Jones JC, Zhen WP, Reed E, et al. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand crosslinks in Chinese hamster ovary [J]. J Biol Chem, 1991,266(11): 7101-7107.
  • 4Sancar A. Excision repair in mammalian cells [J]. J Biol Chem,1995,270(27): 15915-15918.
  • 5Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF [J]. Biochem Pharmacol, 2000,60(9): 1305-1313.
  • 6Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells [J]. Cancer Res, 2002,62 (17):4899-4902.
  • 7Aloyz R, Xu ZY, Bello V, et al. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD [J]. Cancer Res, 2002,62(19) :5457-5462.
  • 8Xu Z, Chen ZP, Malapetsa A, et al. DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program [J]. Anticancer Drugs, 2002,13(5) :511-519.
  • 9Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin [J]. Mutat Res, 2001,478(1-2) :23-43.
  • 10Muotri AR, Marchetto MC, Suzuki MF, et al. Low amounts of the DNA repair XPA protein are sufficient to recover UVresistance [ J ]. Carcinogenesis, 2002,23 (6): 1039-1046.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部